A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease

To investigate the efficacy and safety of Tocilizumab (TCZ) in patients with refractory adult-onset Still’s disease (AOSD). We enrolled 8 female patients from October 2013 to July 2014. All patients fulfilled Japan’s Yamaguch AOSD classification and recognized as refractory AOSD. All Patients receiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ting, Gu, Liyang, Wang, Xiaodong, Guo, Li, Shi, Hui, Yang, Chengde, Chen, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647407/
https://www.ncbi.nlm.nih.gov/pubmed/29044212
http://dx.doi.org/10.1038/s41598-017-13639-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647407/
https://www.ncbi.nlm.nih.gov/pubmed/29044212
http://dx.doi.org/10.1038/s41598-017-13639-y

Ejemplares similares